Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Receivables - Net (2017 - 2025)

Neurocrine Biosciences' Receivables - Net history spans 16 years, with the latest figure at $686.8 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 43.35% year-over-year to $686.8 million; the TTM value through Dec 2025 reached $686.8 million, up 43.35%, while the annual FY2025 figure was $686.8 million, 43.35% up from the prior year.
  • Receivables - Net reached $686.8 million in Q4 2025 per NBIX's latest filing, down from $728.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $728.0 million in Q3 2025 to a low of $147.8 million in Q1 2021.
  • Average Receivables - Net over 5 years is $394.6 million, with a median of $404.7 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: fell 0.54% in 2021, then surged 88.68% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $185.5 million in 2021, then soared by 88.68% to $350.0 million in 2022, then rose by 25.51% to $439.3 million in 2023, then grew by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Receivables - Net are $686.8 million (Q4 2025), $728.0 million (Q3 2025), and $595.7 million (Q2 2025).